Infliximab, a chimeric human-murine anti-TNFα monoclonal antibody, is widely used for the treatment of inflammatory bowel disease (IBD).
MoreIpilimumab (MDX-010), a humanized monoclonal antibody against CTLA-4, causes enhanced T-cell reaction, antitumor response, and significant improvement of the overall survival of patients with metastatic melanoma.
MoreBevacizumab (Avastin), an antiangiogenic anti-VEGF-R monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity, has a rapid impact on tumor-related brain edema in recurrent GB.
MoreBrentuximab vedotin (SGN-35), a CD30-directed antibody-drug conjugate composed of an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent, is approved for treating certain patients with CD30-expressing hematologic malignancies.
MoreCanakinumab, a high-affinity human monoclonal anti IL-1β antibody, neutralizing IL-1β-mediated pathways, is approved for treatment of systemic juvenile idiopathic arthritis (SJIA).
More